

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/937,840
				Filing Date	April 21, 2000 (Int'l)
				First Named Inventor	Patrick SOON-SHIONG
				Art Unit	1614
				Examiner Name	J. Anderson
Sheet	1	of	2	Attorney Docket Number	638772000200

U.S. PATENT DOCUMENTS					
Examiner Initials ²	Cite No. ¹	Document Number Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials ²	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁴
	1.	BELOTTI, D. et al. (November 1996). "The Microtubule-Affecting Drug Paclitaxel Has Antiangiogenic Activity," <i>Clin. Cancer Res.</i> 2(11):1843-1849.				
	2.	BOCCI, G. et al. (December 1, 2002). "Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival <i>in Vitro</i> Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs," <i>Cancer Res.</i> 62(23):6938-6943.				
	3.	European Examination Report mailed on May 6, 2004, for European Application No. 00 928 296.3, filed on April 21, 2000, four pages.				
	4.	JORDAN, M.A. et al. (February 15, 1996). "Mitotic Block Induced in HeLa Cells by Low Concentrations of Paclitaxel (Taxol) Results in Abnormal Mitotic Exit and Apoptotic Cell Death," <i>Cancer Res.</i> 56(4):816-825.				
	5.	LIEBMANN, J.E. et al. (December 1993). "Cytotoxic Studies of Paclitaxel (Taxol [®]) in Human Tumour Cell Lines," <i>Br. J. Cancer</i> 68(6):1104-1109.				
	6.	MERCHAN, J.R. et al. (January 20, 2005; epub. September 28, 2004). "Increased Endothelial Uptake of Paclitaxel as a Potential Mechanism for Its Antiangiogenic Effects: Potentiation by Cox-2 Inhibition," <i>Int. J. Cancer</i> 113(3):490-498.				
	7.	Rote Liste Service GmbH, ed. (1999). "Araniforce [®] " and "Microlut [®] ," <i>Rote Liste 1999</i> , Editio Cantor Verlag: Aulendorf, Germany, Numbers 05 472 and 76 162, six pages. [Translation of entries numbered 05 472 (Araniforce [®]) and 76 162 (Microlut [®]) Only.]				

Not a
Published
document

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/937,840
				Filing Date	April 21, 2000 (Int'l)
				First Named Inventor	Patrick SOON-SHIONG
				Art Unit	1614
				Examiner Name	J. Anderson
Sheet	2	of	2	Attorney Docket Number	638772000200

	8.	WANG, J. et al. (January 2003). "Paclitaxel at Ultra Low Concentrations Inhibits Angiogenesis Without Affecting Cellular Microtubule Assembly," <i>Anticancer Drugs</i> 14(1):13-19.	
--	----	--	--

Examiner Signature	/James Anderson/	Date Considered	07/25/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.